Dow Jones
38.188,72 +285,43 (+0,75%) Nasdaq
15.815,46 +209,97 (+1,35%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0726 +0,0008 (+0,08%) Bitcoin EUR
55.109,29 +1.065,30 (+1,97%) CMC Crypto 200
1.278,26 +7,51 (+0,59%)
GILD Jan 2025 72.500 call
| Chiusura precedente | 2,7500 |
| Aperto | 2,4600 |
| Denaro | 2,5400 |
| Lettera | 2,6400 |
| Prezzo d'esercizio | 72,50 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 2,4600 - 2,5300 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 753 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
